Senseonics (NYSE:SENS) is set to bring the longest-lasting continuous glucose monitor (CGM) to market following a major regulatory nod.

Our sister site, Drug Delivery Business News, reports today that Senseonics received FDA clearance for its next-generation Eversense 365 CGM system.

With the clearance, Eversense 365 becomes the world’s first 365-day CGM system, helping people with type 1 and type 2 diabetes aged 18 years and older monitor their condition. The system also received clearance as an integrated CGM (iCGM) system, meaning it can work with compatible medical devices. Those include insulin pumps as part of automated insulin delivery systems.

Get the full story at our sister site, Drug Delivery Business News.